Introductory Remarks on the Development of Isosorbide-5-Mononitrate

  • U. Abshagen
Conference paper
Part of the International Boehringer Mannheim Symposia book series (BOEHRINGER)


The development of IS-5-MN as a useful drug for the prophylactic treatment of angina pectoris appears to be the final outcome of a wrong conclusion made 12 years ago. At that time and on several occasions later, Needleman et al. [9] claimed that orally administered organic nitrates were inactive due to their complete metabolic inactivation during their first passage through the liver. This provocative thesis stimulated interest in both the pharmacokinetics and pharmacodynamics of the metabolites produced. In the case of ISDN, it was already known from experiments in dogs that IS-5-MN is the main metabolite present in plasma [10], and this was later shown to apply to man, too [6]. At the same time, Wendt [15] as well as Bogaert and Rosseel [5] were able to demonstrate in isolated organs that the two mononitrates of isosorbide exhibit a definite nitrate-typical vascular activity, although it was less than that of the parent compound. Stauch et al. [12] and Michel [8] were then the first to show antianginal activity after injection i.v. or into the pulmonary artery of coronary patients.


Isosorbide Dinitrate Introductory Remark Organic Nitrate Coronary Patient Nitrate Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Abshagen U, Spörl-Radun S (1980) Pharmacokinetics and effect of 5-Isosorbide-mononitrate (5-ISMN) in normal man. World Conference on Clinical Pharmacology and Therapeutics. Macmillan, London, p 0377Google Scholar
  2. 2.
    Abshagen U, Spörl-Radun S (1981) First data on effects and pharmacokinetics of isosorbide-5-mononitrate in normal man. Eur J Clin Pharmacol 19: 423–429PubMedCrossRefGoogle Scholar
  3. 3.
    Abshagen U, Betzien G, Endele R, Kaufmann B (1981 a) Pharmacokinetics of intravenous and oral isosorbide-5-mononitrate. Eur J Clin Pharmacol 20: 269–275PubMedCrossRefGoogle Scholar
  4. 4.
    Abshagen U, Spörl-Radun S, Betzien G, Kaufmann B, Endele R (1981 b) Pharmakokinetic, Wirkung und Verträglichkeit von Isosorbiddinitrat und Isosorbid-5-Mononitrat bei gesunden Versuchspersonen. Med Welt 32/14a: 508–516Google Scholar
  5. 5.
    Bogaert MG, Rosseel MT (1972) Vascular effects of the dinitrate and mononitrate esters of isosorbide, isomannide and isoidide. Naunyn Schmiedebergs Arch Pharmacol 275: 339–342PubMedCrossRefGoogle Scholar
  6. 6.
    Down WH, Chasseaud LF, Grundy RK (1974) Biotransformation of isosorbide dinitrate in humans. J Pharm Sci 63:1147–1149PubMedCrossRefGoogle Scholar
  7. 7.
    Dietmann K, Sponer G, Voss E (1981) Pharmakodynamik, Pharmakokinetik und Metabolismus der Nitrate des Isosorbids am wachen Hund. Med Welt 32/14a: 481–490Google Scholar
  8. 8.
    Michel D (1976) Der Einfluß von Metaboliten des Isosorbiddinitrats auf das Belastungs-EKG bei Koronarinsuffizienz. Herz/Kreisl 8: 444–447Google Scholar
  9. 9.
    Needleman P, Lang S, Johnson EM Jr (1972) Organic nitrates: Relationship between biotransformation and rational angina pectoris therapy. J Pharmacol Exp Ther 181: 489–497PubMedGoogle Scholar
  10. 10.
    Sisenwine SF, Ruelius HW (1971) Plasma concentrations and urinary excretion of isosorbide dinitrate and its metabolites in the dog. J Pharmacol Exp Ther 176: 296–301PubMedGoogle Scholar
  11. 11.
    Sponer G, Kiihnle HF, Strein K, Bartsch W, Endele R, Dietmann K (1983) Pharmacokinetic aspects of isosorbide-5-mononitrate in dogs. J Pharmacol Exp Ther 228: 235–239Google Scholar
  12. 12.
    Stauch M, Grewe N, Nissen H (1975) Die Wirkung von 2- und 5-Isosorbidmononitrat auf das Belastungs-EKG von Patienten mit Koronarinsuffizienz. Verh Dtsch Ges Kreislaufforsch 41: 182–184PubMedGoogle Scholar
  13. 13.
    Strein K, Bartsch W, Sponer G, Müller-Beckmann B, Lexa P (1984a) Differences in the nitrate ion formation and the toxicological findings between isosorbide dinitrate and isosorbide-5-mononitrate. Toxikol Appl Pharmacol 72: 142–147CrossRefGoogle Scholar
  14. 14.
    Strein K, Sponer G, Bartsch W, Müller-Beckmann B, Dietmann K (1984b) Electrocardiographic analysis of the effects of isosorbide-5-mononitrate on regional myocardial ischemia in conscious dogs. J Pharmacol Exp Ther (in press)Google Scholar
  15. 15.
    Wendt RL (1972) Systemic and coronary vascular effects of the 2- and the 5-mononitrate esters of isosorbide. J Pharmacol Exp Ther 180: 732–742PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1985

Authors and Affiliations

  • U. Abshagen

There are no affiliations available

Personalised recommendations